

Special Issue

Research on HIV/AIDS Vaccine

Message from the Guest Editors

The development and accessibility of highly active antiretroviral treatment (ART) represent a significant step, but suboptimal adherence and drug resistance remain major challenges. Millions of people living with HIV still lack access to ART. Although ART is essential in preventing HIV transmission, alone it cannot end the pandemic. Therefore, developing an HIV vaccine is a global health priority and the only way to put an end to the HIV and AIDS pandemic. This Special Issue highlights recent scientific and technical advancements made in this field, including correlates of protection, immune pathways, mechanisms for addressing ART unmet needs, and recent advances in novel prophylactic and therapeutic vaccines. We invite contributions including original reports, original observations, or reviews to highlight (i) correlates of protection, (ii) immune pathways after primary infection, (iii) mechanisms for addressing ART unmet needs such as persistent viral replication in compartments and reservoirs insensitive to ART, chronic immune activation, and the incomplete restoration of B and T cells, and (iv) recent advances in novel prophylactic and therapeutic vaccines.

Guest Editors

Dr. Portia Chipo Mutevedzi

Child Health and Mortality Prevention Surveillance (CHAMPS), Emory University, Atlanta, GA, USA

Dr. Nagesh Kolishetti

Department of Immunology and Nano-Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA

Deadline for manuscript submissions

31 May 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/204139

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).